NCT06253221Active, not recruitingPhase 3
A Study of Mavacamten in Adolescent Participants with Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (age 12 years to < 18 years) with Symptomatic Obstructive Hypertrophic Cardiomyopathy (SCOUT-HCM)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 6 Jul 2026
Brief summary (registry, in English)
To evaluate the effect of mavacamten compared to placebo on left ventricular outflow tract (LVOT) obstruction in adolescents with symptomatic obstructive HCM
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 11 (estimated)
- First submitted
- 15 Jan 2024
- Start date
- 27 Aug 2024
- Lead sponsor
- Bristol-Myers Squibb Services Unlimited Company
- Diseases
- Hypertrophic cardiomyopathy
- EU CT number
- 2023-505650-17-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 11
- 8 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Phenocopy diseases resulting in myocardial hypertrophy not related to sarcomere dysfunction
- Planned escalation in HCM therapy or upcoming intervention (eg, major cardiac surgery, HCM medication dose increase)
Lab values
- Evidence of LVEF <50% in prior 6 months
Who the study is looking for
- Adolescents aged 12 to <18 at the time of agreeing to participate
- Diagnosis of HCM
- Presence of LVOT obstruction
- Presence of symptoms
Age in the registry: - to 17 years · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Universitaetsmedizin Berlin KöR Coordinator of this site? Confirm its status | Berlin | Germany | Active, not recruiting |
| Deutsches Herzzentrum Muenchen Des Freistaates Bayern Klinik An Der Technischen Universitaet Muenchen Coordinator of this site? Confirm its status | Munich | Germany | Active, not recruiting |
| Sant Joan De Deu Barcelona Hospital Coordinator of this site? Confirm its status | Esplugues De Llobregat | Spain | Active, not recruiting |
| Hospital Universitario La Paz Coordinator of this site? Confirm its status | Madrid | Spain | Active, not recruiting |
| Hopital Necker Enfants Malades Coordinator of this site? Confirm its status | Paris | France | Active, not recruiting |
| Centre Hospitalier Universitaire de Bordeaux Coordinator of this site? Confirm its status | Pessac | France | Active, not recruiting |
| Children's Health Ireland Coordinator of this site? Confirm its status | Dublin | Ireland | Active, not recruiting |
| Azienda Ospedaliera Universitaria Meyer IRCCS Coordinator of this site? Confirm its status | Florence | Italy | Active, not recruiting |
Related publications
- Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy.N Engl J Med · 2026 · PMID 41910394
This page is information, not medical advice. Discuss any trial with your doctor.